JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esposito, V
Right arrow Articles by Caputi, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esposito, V
Right arrow Articles by Caputi, M
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lung Cancer
Journal of Clinical Pathology 2005;58:734-739
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer

V Esposito1, A Baldi2, A De Luca3, G Tonini4, B Vincenzi4, D Santini4, P Persichetti5, A Mancini6, G Citro7, F Baldi2, A M Groeger1, M Caputi6

1 International Society for the Study of Comparative Oncology (ISSCO), Silver Spring, MD 209 06, USA
2 Department of Biochemistry and Biophysics "F. Cedrangolo", Section of Anatomic Pathology, Second University of Naples, Naples 80138, Italy
3 Department of Medicine and Public Health, Section of Clinical Anatomy, Second University of Naples
4 Section of Oncology, Campus BioMedico University, Rome 00100, Italy
5 Section of Plastic and Reconstructive Surgery, Campus BioMedico University
6 Department of Cardiological, Respiratory and Thoracic Medical Sciences, Second University of Naples
7 SAFU Department, Regina Elena Cancer Institute, Rome 00100, Italy

Correspondence to:
Dr A Baldi
Via G. Orsi 25, 80128 Naples, Italy; alfonsobaldi{at}tiscali.it Background: Experimental evidence suggests that lung cancer development and progression can be linked to an increased proliferation rate.

Aims/Methods: To evaluate the immunohistochemical expression of seven components of the cell cycle machinery in a series of well characterised non-small cell lung cancer (NSCLC) specimens (n = 105).

Results: Multivariate analysis revealed that simultaneous loss of expression of three of these factors—cyclin D1, the cyclin dependent kinase inhibitor p16, and the tumour suppressor retinoblastoma protein Rb2/p130—correlated with survival, confirming the hypothesis that the cyclin D1–p16–retinoblastoma tumour suppressor pathway is inactivated in most lung cancer samples.

Conclusions: These results suggest that loss of control of cell cycle checkpoints is a common occurrence in lung cancer and support the idea that functional cooperation between different cell cycle regulatory proteins constitutes another level of regulation in cell growth control and tumour suppression.


Abbreviations: CI, confidence interval; NSCLC, non-small cell lung cancer; PCNA, proliferating nuclear cell antigen; pRb, retinoblastoma protein

Keywords: non-small cell lung cancer; p53; pRb2/p130; p16; cyclin D1; immunohistochemistry; prognosis




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
C-Q Zhu, W Shih, C-H Ling, and M-S Tsao
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.
J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.